10x Genomics (NASDAQ:TXG - Get Free Report) Director John Stuelpnagel sold 20,000 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the sale, the director directly owned 328,436 shares in the company, valued at $20,280,923. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
10x Genomics Stock Performance
Shares of TXG stock opened at $65.60 on Wednesday. 10x Genomics has a 52-week low of $11.16 and a 52-week high of $66.94. The stock has a market cap of $8.55 billion, a price-to-earnings ratio of -111.18 and a beta of 2.08. The firm has a fifty day moving average of $51.97 and a 200-day moving average of $34.09.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The company had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. During the same period last year, the firm earned $0.28 EPS. The firm's revenue for the quarter was down 12.7% compared to the same quarter last year. On average, sell-side analysts predict that 10x Genomics will post -0.75 earnings per share for the current year.
Analysts Set New Price Targets
TXG has been the subject of a number of analyst reports. Zacks Research cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 18th. Stifel Nicolaus set a $50.00 price objective on 10x Genomics in a research note on Friday, August 7th. Royal Bank Of Canada started coverage on 10x Genomics in a report on Tuesday, September 1st. They issued a "sector perform" rating and a $70.00 target price for the company. JPMorgan Chase & Co. increased their target price on 10x Genomics from $17.00 to $20.00 and gave the stock a "neutral" rating in a report on Tuesday, May 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of 10x Genomics in a research report on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $40.57.
View Our Latest Analysis on TXG
Institutional Investors Weigh In On 10x Genomics
Hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC increased its position in shares of 10x Genomics by 164.4% during the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company's stock worth $39,000 after purchasing an additional 1,470 shares in the last quarter. Fifth Third Bancorp acquired a new position in 10x Genomics in the first quarter valued at about $50,000. Elevation Wealth Partners LLC grew its stake in 10x Genomics by 332.3% during the second quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company's stock worth $57,000 after buying an additional 1,143 shares during the last quarter. Van ECK Associates Corp grew its stake in 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company's stock worth $60,000 after buying an additional 1,695 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company's stock worth $87,000 after buying an additional 5,025 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
